31st July 2015

European approval for Roche’s next-gen breast cancer drug

Perjeta now available in EU for use before surgery in early stage aggressive breast cancer. Roche’s new oncology drug Perjeta (pertuzumab) has been approved by the European Commission to treat certain breast cancer patients when used in combination with its ageing drug Herceptin (trastuzumab).


28th July 2015

Sanofi and Regeneron extend partnership to cancer

Sanofi will pay up to $2.2bn to its long-term biotech partner Regeneron to research and market new immunotherapies in cancer. The two firms, which already co-develop and market the newly approved PCKS9 cholesterol drug Praluent (alirocumab), will work together on early-stage testing of a PD-1 drug candidate for undisclosed targets.


JULY 22, 2015

Merck & Co’s Keytruda approved in EU for melanoma

Merck & Co’s anti-PD-1 therapy Keytruda has been approved in Europe for the treatment of advanced skin cancer. Keytruda will compete for market share with BMS’ Opdivo (nivolumab), the first PD-1 inhibitor to bag European approval when it was cleared for advanced melanoma last month.


Jul 15, 2015

Celgene to Acquire Receptos for $7.2B

Celgene Corp. announced it has signed an agreement to acquire Receptos. Under the terms of the merger, Celgene will pay $232 per share in cash, or a total of approximately $7.2 billion, net of cash acquired

 

JULY 29, 2015

Eisai’s Lenvima breakthrough therapy for new indication

The FDA has granted Eisai’s promising cancer drug Lenvima breakthrough therapy designation for renal cell carcinoma. The designation is based on the results of a Phase II trial that showed that Lenvima plus Novartis’ Afinitor (everolimus) “significantly” extended progression-free survival (PFS) compared to Afinitor alone


JULY 27, 2015

Novartis melanoma, anaemia drugs win CHMP favour

European regulatory advisors are backing approval of Novartis’ experimental melanoma combination therapy Tafinlar and Mekinist as well as Revolade for severe aplastic anaemia


JULY 17, 2015

Amgen leukaemia drug impresses in new indication

Amgen’s leukaemia immunotherapy Blincyto has demonstrated complete remission in a phase II trial testing the drug in patients with Philadelphia chromosome-positive (Ph+) B-cell precursor acute lymphoblastic leukemia (ALL).

July 13, 2015

Gefitinib (Iressa) Back in the US for Lung Cancer, Now as First-Line

The US Food and Drug Administration today announced the approval of gefitinib (Iressa, AstraZeneca) for the first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors contain specific types of epidermal growth factor receptor (EGFR) gene mutations.

Jun 30, 2015

Celgene to Pay $1 Billion for Decade-long Partnership with Juno Therapeutics

Celgene and Juno Therapeutics will enter into a decade-long partnership to develop and commercialize immunotherapies for the treatment of cancer and autoimmune diseases, both companies announced on June 29, 2015. The partnership will focus on the development of CAR T-cell therapies and other programs related to T-cell technology.

8th May 2015

EMA clears Novartis’ lung cancer drug Zykadia

Zykadia (ceritinib) becomes the first treatment option approved in Europe for patients with ALK-positive non-small cell lung cancer (NSCLC) whose disease has progressed despite prior therapy with Pfizer/Merck KGaA’s Xalkori (crizotinib).

Luca Dezzani

@LucaDezzani

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s